

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season

as of March 25, 2021

| | A(H1N1)pdm09 | | | | | | A(H3N2) | | | | | | B | | | | |
|-----------------------------------|---------------------------|---------------------------|---------------------------|-----------|-------------|--------------|-----------|-------------|-----------|-----------|-------------|--------------|-----------|-------------|-----------|-----------|-------------|
| | Baloxavir | Oseltamivir | Peramivir | Zanamivir | Laninamivir | Amantadine | Baloxavir | Oseltamivir | Peramivir | Zanamivir | Laninamivir | Amantadine | Baloxavir | Oseltamivir | Peramivir | Zanamivir | Laninamivir |
| Resistant (%) | 1 ^a (0.12%) | 41 ^b (1.5%) | 41 ^b (1.5%) | 0 | 0 | 82 (100%) | 0 | 0 | 0 | 0 | 0 | 37 (100%) | 0 | 0 | 0 | 0 | 0 |
| Number of viruses tested | 831 | 2,658 | 2,658 | 375 | 375 | 82 | 80 | 90 | 90 | 90 | 90 | 37 | 130 | 149 | 149 | 149 | 149 |
| Number of viruses reported | 5,119 | | | | | | 132 | | | | | | 743 | | | | |

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

^a Patients without treatment 1

^b Patients without treatment 28